The seven (7) peptide bulk drug substances expected to be considered by the PCAC in July, together with the uses identified for evaluation, are: July 23, 2026 : BPC-157 (free base and acetate): ulcerative colitis KPV (free base and acetate): wound healing and inflammatory conditions Thymosin Beta-4, Fragment (LKKTETQ)(TB-500) (free base and acetate): wound healing MOTs-C (free base and acetate): obesity and osteoporosis July 24, 2026 : Emideltide (DSIP) (free base and acetate): opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate): cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate): insomnia The peptide substances scheduled for consideration at the July 23-24, 2026, PCAC meeting are among those identified for removal from Category 2
10.1177/0960327114567766 55 LiW.GuoY.ZhangC.WuR.YangA
Regular imaging (MRI of the primary site and CT of the chest) every 36 months for the first 23 years post-treatment is recommended due to the high risk of recurrence
We do not endorse supplement use or any product or supplement vendor, and all discussion here is for scientific interest
Protease inhibition as new therapeutic strategy for GI diseases
